|
1
|
GBD 2017 Disease and Injury Incidence and
Prevalence Collaborators. Global, regional, and national incidence,
prevalence, and years lived with disability for 354 diseases and
injuries for 195 countries and territories, 1990-2017: A systematic
analysis for the global burden of disease study 2017. Lancet.
392:1789–1858. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Saeedi P, Petersohn I, Salpea P, Malanda
B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA,
Ogurtsova K, et al: Global and regional diabetes prevalence
estimates for 2019 and projections for 2030 and 2045: Results from
the international diabetes federation diabetes atlas, 9(th)
edition. Diabetes Res Clin Pract. 157(107843)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rezk NA, Sabbah NA and Saad MS: Role of
MicroRNA 126 in screening, diagnosis, and prognosis of diabetic
patients in Egypt. IUBMB Life. 68:452–458. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Zhang T, Li L, Shang Q, Lv C, Wang C and
Su B: Circulating miR-126 is a potential biomarker to predict the
onset of type 2 diabetes mellitus in susceptible individuals.
Biochem Biophys Res Commun. 463:60–63. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zampetaki A, Kiechl S, Drozdov I, Willeit
P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E,
et al: Plasma microRNA profiling reveals loss of endothelial
miR-126 and other microRNAs in type 2 diabetes. Circ Res.
107:810–817. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Guay C and Regazzi R: Circulating
microRNAs as novel biomarkers for diabetes mellitus. Nat Rev
Endocrinol. 9:513–521. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nunez Lopez YO, Garufi G and Seyhan AA:
Altered levels of circulating cytokines and microRNAs in lean and
obese individuals with prediabetes and type 2 diabetes. Mol
Biosyst. 13:106–121. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jones A, Danielson KM, Benton MC, Ziegler
O, Shah R, Stubbs RS, Das S and Macartney-Coxson D: miRNA
signatures of insulin resistance in obesity. Obesity (Silver
Spring). 25:1734–1744. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mao Y, Mohan R, Zhang S and Tang X:
MicroRNAs as pharmacological targets in diabetes. Pharmacol Res.
75:37–47. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu Y, Gao G, Yang C, Zhou K, Shen B,
Liang H and Jiang X: The role of circulating microRNA-126
(miR-126): A novel biomarker for screening prediabetes and newly
diagnosed type 2 diabetes mellitus. Int J Mol Sci. 15:10567–10577.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Willeit P, Skroblin P, Moschen AR, Yin X,
Kaudewitz D, Zampetaki A, Barwari T, Whitehead M, Ramírez CM,
Goedeke L, et al: Circulating MicroRNA-122 is associated with the
risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes.
66:347–357. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Regmi A, Liu G, Zhong X, Hu S, Ma R, Gou
L, Zafar MI and Chen L: Evaluation of serum microRNAs in patients
with diabetic kidney disease: A nested case-controlled study and
bioinformatics analysis. Med Sci Monit. 25:1699–1708.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tao H, Wang MM, Zhang M, Zhang SP, Wang
CH, Yuan WJ, Sun T, He LJ and Hu QK: MiR-126 suppresses the
glucose-stimulated proliferation via IRS-2 in INS-1 β cells. PLoS
One. 11(e0149954)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hu Y, Li Y, Chen C, Zhu S, Guo M, Liu S,
Zheng J, Qin N and Xu L: Identification of miR-126 knockdown mouse
and the change of blood glucose. Zhong Nan Da Xue Xue Bao Yi Xue
Ban. 40:12–17. 2015.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
16
|
Lin H, Tas E, Børsheim E and Mercer KE:
Circulating miRNA signatures associated with insulin resistance in
adolescents with obesity. Diabetes Metab Syndr Obes. 13:4929–4939.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Al-Kafaji G, Al-Mahroos G, Al-Muhtaresh
HA, Skrypnyk C, Sabry MA and Ramadan AR: Decreased expression of
circulating microRNA-126 in patients with type 2 diabetic
nephropathy: A potential blood-based biomarker. Exp Ther Med.
12:815–822. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Weale CJ, Matshazi DM, Davids SFG,
Raghubeer S, Erasmus RT, Kengne AP, Davison GM and Matsha TE:
MicroRNAs-1299, -126-3p and -30e-3p as potential diagnostic
biomarkers for prediabetes. Diagnostics (Basel).
11(949)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wells G, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses. Ottawa Health Research Institute, Ottawa, ON,
1999.
|
|
20
|
Liu F, Chen G, Huo W, Wang C, Liu S, Li N,
Mao S, Hou Y, Lu Y and Xiang H: Associations between long-term
exposure to ambient air pollution and risk of type 2 diabetes
mellitus: A systematic review and meta-analysis. Environ Pollut.
252:1235–1245. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hamling J, Lee P, Weitkunat R and Ambühl
M: Facilitating meta-analyses by deriving relative effect and
precision estimates for alternative comparisons from a set of
estimates presented by exposure level or disease category. Stat
Med. 27:954–970. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials revisited. Contemp Clin Trials. 45:139–145.
2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cheung MW and Cheung SF: Random-effects
models for meta-analytic structural equation modeling: Review,
issues, and illustrations. Res Synth Methods. 7:140–155.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nakagawa S and Cuthill IC: Effect size,
confidence interval and statistical significance: A practical guide
for biologists. Biol Rev Camb Philos Soc. 82:591–605.
2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wei X, Zhang Y, Tao H, Tang H, Chen H and
Zeng X: Meta analysis of correlation coefficient data using meta
package and metafor package of R software. Chin J Evid-Based Med.
15:855–860. 2015.(In Chinese).
|
|
26
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558.
2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kulinskaya E and Dollinger MB: Commentary
on ‘Misunderstandings about Q and ‘Cochran's Q test’ in meta
analysis’. Stat Med. 35:501–502. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Liu X, Luo X, Liu Y, Sun X, Han C, Zhang
L, Wang B, Ren Y, Zhao Y, Zhang D, et al: Resting heart rate and
risk of metabolic syndrome in adults: A dose-response meta-analysis
of observational studies. Acta Diabetol. 54:223–235.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Egger M, Smith GD, Schneider M and Minder
C: Bias in meta-analysis detected by a simple, graphical test. BMJ.
315:629–634. 1997.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994.PubMed/NCBI
|
|
31
|
Al-Kafaji G, Al-Mahroos G, Al-Muhtaresh
HA, Sabry MA, Razzak RA and Salem AH: Circulating
endothelium-enriched microRNA-126 as a potential biomarker for
coronary artery disease in type 2 diabetes mellitus patients.
Biomarkers. 22:268–278. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang X, Sundquist J, Zöller B, Memon AA,
Palmér K, Sundquist K and Bennet L: Determination of 14 circulating
microRNAs in Swedes and Iraqis with and without diabetes mellitus
type 2. PLoS One. 9(e86792)2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ezaz G, Trivedi HD, Connelly MA, Filozof
C, Howard K, Parrish ML, Kim M, Herman MA, Nasser I, Afdhal NH, et
al: Differential associations of circulating MicroRNAs with
pathogenic factors in NAFLD. Hepatol Commun. 4:670–680.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nie H, Hu H, Li Z, Wang R, He J, Li P, Li
W, Cheng X, An J, Zhang Z, et al: Associations of plasma metal
levels with type 2 diabetes and the mediating effects of microRNAs.
Environ Pollut. 292(118452)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yuan JF: Serum miRNA expression and
clinical value in patients with type 2 diabetes mellitus
complicated with coronary atherosclerosis (Master thesis). Jiangsu
University, R541.4; R587.1, 2019 (In Chinese).
|
|
36
|
Wan SJ, Wang C, Wang J, Niu DM, Zhang CN
and Wang JJ: Study on serum levels of miR-16, miR-126 and miR-221
and their clinical significance in type 2 diabetes patients with or
without microvascular complications. J Modern Laboratory Medicine.
31:9–13. 2016.
|
|
37
|
Zhang YD, Gao QC, Zhao R, Pu YF, Li SH and
Wei JF: Correlation between serum miR-126, VEGF levels and insulin
resistance in patients with newly diagnosed Type 2 Diabetes
Mellitus. Int J Lab Med. 41:935–938. 2020.(In Chinese).
|
|
38
|
Zhou N, Liang J, Teng F, Zou CY, Yang MQ,
Qi L and Song HD: Effect of abnormal glucose metabolism on
expression of serum microRNA in patients with coronary heart
disease. Chin J Geriatr Heart Brain Vessel Dis. 15:14–17. 2013.(In
Chinese).
|
|
39
|
Wang L, Zeng N, Xie WP, Jiang YL, Li Z,
Tang LZ, Long CD and Wu BL: Effect of intensive blood glucose and
blood pressure control on exosomal effect microRNA in patients with
diabetic foot. Chin Youjiang Med J. 49:97–102. 2021.(In
Chinese).
|
|
40
|
Lv YB and Pan ZQ: The impact of abnormal
glucose metabolism on mir-126 in progenitor cells to patients with
coronary heart disease. J Clin Cardiol (China). 31:1061–1064.
2015.(In Chinese).
|
|
41
|
Gao W, Liu YZ, Wang LJ, Fang BH and Lei
NY: Expression of miR-126 in PBMCs of diabetic retinopathy
patients. Chin J Pract Ophthalmol. 34:322–325. 2016.(In
Chinese).
|
|
42
|
Chong XJ, Yu QY and Yang LX: Expression
and clinical significance of miR-126 and sVCAM-1 in patients with
type 2 diabetic nephropathy. Hebei Med J. 41:334–337+342. 2019.(In
Chinese).
|
|
43
|
Ren Y, Huang T and Shi X: The change of
expression level of circulating miRNA-126 in patients with type 2
diabetes and its relative factors. Chin J Diabet. 22:633–636.
2014.(In Chinese).
|
|
44
|
Ortega FJ, Mercader JM, Moreno-Navarrete
JM, Rovira O, Guerra E, Esteve E, Xifra G, Martinez C, Ricart W,
Rieusset J, et al: Profiling of circulating microRNAs reveals
common microRNAs linked to type 2 diabetes that change with insulin
sensitization. Diabetes Care. 37:1375–1383. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Olivieri F, Spazzafumo L, Bonafè M,
Recchioni R, Prattichizzo F, Marcheselli F, Micolucci L, Mensà E,
Giuliani A, Santini G, et al: MiR-21-5p and miR-126a-3p levels in
plasma and circulating angiogenic cells: Relationship with type 2
diabetes complications. Oncotarget. 6:35372–35382. 2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Olivieri F, Bonafè M, Spazzafumo L, Gobbi
M, Prattichizzo F, Recchioni R, Marcheselli F, La Sala L, Galeazzi
R, Rippo MR, et al: Age- and glycemia-related miR-126-3p levels in
plasma and endothelial cells. Aging (Albany NY). 6:771–787.
2014.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Giannella A, Radu CM, Franco L, Campello
E, Simioni P, Avogaro A, de Kreutzenberg SV and Ceolotto G:
Circulating levels and characterization of microparticles in
patients with different degrees of glucose tolerance. Cardiovasc
Diabetol. 16(118)2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ghaneh T, Zeinali F, Babini H, Astaraki S
and Hassan-Zadeh V: An increase in the expression of circulating
miR30d-5p and miR126-3p is associated with intermediate
hyperglycaemia in Iranian population. Arch Physiol Biochem.
1-8(1839105)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Flowers E, Ramirez-Mares JD,
Velazquez-Villafana M, Rangel-Salazar R, Sucher A, Kanaya AM,
Aouizerat BE and de la Vega Monroy ML: Circulating microRNAs
associated with prediabetes and geographic location in Latinos. Int
J Diabetes Dev Ctries. 41:570–578. 2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Amr KS, Abdelmawgoud H, Ali ZY, Shehata S
and Raslan HM: Potential value of circulating microRNA-126 and
microRNA-210 as biomarkers for type 2 diabetes with coronary artery
disease. Br J Biomed Sci. 75:82–87. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Hess AL, Larsen LH, Udesen PB, Sanz Y,
Larsen TM and Dalgaard LT: Levels of circulating miR-122 are
associated with weight loss and metabolic syndrome. Obesity (Silver
Spring). 28:493–501. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Guo XL, Chen Y, Ma WG, Wang QY, Du Y and
Li SS: Clinical significance of miR-126 as marker in the diagnosis
of type 2 diabetic kidney disease. J Clin Nephrol. 17:361–365.
2017.(In Chinese).
|
|
53
|
Bao W: Heme oxygenase-1, plasma ferritin
levels and type 2 diabetes. PhD dissertation, Huazhong University
of Science and Technology, R587.1, 2011 (In Chinese).
|
|
54
|
Chen Q, Zhang YD, Wu SN, Chen YX, Liu XJ
and Wei HY: Correlation between serum microRNA-122 and insulin
resistance in obese children. Zhongguo Dang Dai Er Ke Za Zhi.
21:910–914. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
55
|
Dong L, Hou X, Liu F, Tao H, Zhang Y, Zhao
H and Song G: Regulation of insulin resistance by targeting the
insulin-like growth factor 1 receptor with microRNA-122-5p in
hepatic cells. Cell Biol Int. 43:553–564. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Wang R, Hong J, Cao Y, Shi J, Gu W, Ning
G, Zhang Y and Wang W: Elevated circulating microRNA-122 is
associated with obesity and insulin resistance in young adults. Eur
J Endocrinol. 172:291–300. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Zhu JH, Wang JL, Feng ZX, Chen AL, Huang J
and Du WS: Expression and clinical significance of miR-122 in
patients with diabetes mellitus and chronic hepatitis B. Lab Med
Clin Pract. 17:582–585. 2020.
|
|
58
|
Mohany KM, Al Rugaie O, Al-Wutayd O and
Al-Nafeesah A: Investigation of the levels of circulating miR-29a,
miR-122, sestrin 2 and inflammatory markers in obese children
with/without type 2 diabetes: A case control study. BMC Endocr
Disord. 21(152)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
González-Arce LM, Lara-Riegos JC,
Pérez-Mendoza GJ, Rubí-Castellanos R, Vega-Marcín M,
Valencia-Pacheco G, Torres-Romero JC and González-Herrera L: High
expression levels of circulating microRNA-122 and microRNA-222 are
associated with obesity in children with Mayan ethnicity. Am J Hum
Biol. 33(e23540)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Refeat MM, Hassan NAM, Ahmad IH, Mostafa
ERM and Amr KS: Correlation of circulating miRNA-33a and miRNA-122
with lipid metabolism among Egyptian patients with metabolic
syndrome. J Genet Eng Biotechnol. 19(147)2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Krause BJ, Carrasco-Wong I, Dominguez A,
Arnaiz P, Farías M, Barja S, Mardones F and Casanello P: Micro-RNAs
Let7e and 126 in plasma as markers of metabolic dysfunction in 10
to 12 years old children. PLoS One. 10(e0128140)2015.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Seyhan AA, Nunez Lopez YO, Xie H, Yi F,
Mathews C, Pasarica M and Pratley RE: Pancreas-enriched miRNAs are
altered in the circulation of subjects with diabetes: a pilot
cross-sectional study. Sci Rep. 6(31479)2016.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Song B, Fu L and Liu J: Association
between serum miR-126 and non-alcoholic fatty liver disease in
patients with newly diagnosed type 2 diabetes mellitus. Chin J
Diabet. 26:812–816. 2018.(In Chinese).
|
|
64
|
Lin MP and Wang JJ: Expression of
microRNA-126 and microRNA-155 in patients of coronary heart disease
combined with impaired glucose tolerance and intervention of
acarbose. J Clin Intern Med. 36:108–112. 2019.(In Chinese).
|
|
65
|
Zeinali F, Zarch SMA, Jahan-Mihan A,
Kalantar SM, Mehrjardi MYV, Fallahzadeh H, Hosseinzadeh M,
Rahmanian M and Mozaffari-Khosravi H: Circulating microRNA-122,
microRNA-126-3p and microRNA-146a are associated with inflammation
in patients with pre-diabetes and type 2 diabetes mellitus: A case
control study. PLoS One. 16(e0251697)2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Flowers E, Kanaya AM, Zhang L and
Aouizerat BE: The role of racial and ethnic factors in microRNA
expression and risk for type 2 diabetes. Front Genet.
13(853633)2022.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Spanakis EK and Golden SH: Race/ethnic
difference in diabetes and diabetic complications. Curr Diab Rep.
13:814–23. 2013.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Centers for Disease Control and Prevention
(CDC): National Diabetes Statistics Report. CDC Atlanta, GA, 2020.
https://www.cdc.gov/diabetes/data/statistics-report/.
Accessed May 3, 2022.
|
|
69
|
Meeks KA, Freitas-Da-Silva D, Adeyemo A,
Beune EJ, Modesti PA, Stronks K, Zafarmand MH and Agyemang C:
Disparities in type 2 diabetes prevalence among ethnic minority
groups resident in Europe: A systematic review and meta-analysis.
Intern Emerg Med. 11:327–340. 2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Zhang T, Lv C, Li L, Chen S, Liu S, Wang C
and Su B: Plasma miR-126 is a potential biomarker for early
prediction of type 2 diabetes mellitus in susceptible individuals.
Biomed Res Int. 2013(761617)2013.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Ryu HS, Park SY, Ma D, Zhang J and Lee W:
The induction of microRNA targeting IRS-1 is involved in the
development of insulin resistance under conditions of mitochondrial
dysfunction in hepatocytes. PLoS One. 6(e17343)2011.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Oses M, Sanchez JM, Portillo MP, Aguilera
CM and Labayen I: Circulating miRNAs as biomarkers of obesity and
obesity-associated comorbidities in children and adolescents: A
systematic review. Nutrients. 11(2890)2019.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Heishima K, Ichikawa Y, Yoshida K, Iwasaki
R, Sakai H, Nakagawa T, Tanaka Y, Hoshino Y, Okamura Y, Murakami M,
et al: Circulating microRNA-214 and -126 as potential biomarkers
for canine neoplastic disease. Sci Rep. 7(2301)2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Cantaluppi V, Biancone L, Figliolini F,
Beltramo S, Medica D, Deregibus MC, Galimi F, Romagnoli R,
Salizzoni M, Tetta C, et al: Microvesicles derived from endothelial
progenitor cells enhance neoangiogenesis of human pancreatic
islets. Cell Transplant. 21:1305–1320. 2012.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Castaño C, Kalko S, Novials A and Párrizas
M: Obesity-associated exosomal miRNAs modulate glucose and lipid
metabolism in mice. Proc Natl Acad Sci USA. 115:12158–12163.
2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Jamwal S and Sharma S: Vascular
endothelium dysfunction: A conservative target in metabolic
disorders. Inflamm Res. 67:391–405. 2018.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Wang S, Aurora AB, Johnson BA, Qi X,
McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The
endothelial-specific microRNA miR-126 governs vascular integrity
and angiogenesis. Dev Cell. 15:261–271. 2008.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh
RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D:
miR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Wang Y and Yan H: MicroRNA-126 contributes
to niaspan treatment induced vascular restoration after diabetic
retinopathy. Sci Rep. 6(26909)2016.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Nigi L, Grieco GE, Ventriglia G, Brusco N,
Mancarella F, Formichi C, Dotta F and Sebastiani G: MicroRNAs as
regulators of insulin signaling: Research updates and potential
therapeutic perspectives in type 2 diabetes. Int J Mol Sci.
19(3705)2018.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Willeit P, Skroblin P, Kiechl S,
Fernández-Hernando C and Mayr M: Liver microRNAs: potential
mediators and biomarkers for metabolic and cardiovascular disease?
Eur Heart J. 37:3260–3266. 2016.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Dedov I, Shestakova M, Benedetti MM, Simon
D, Pakhomov I and Galstyan G: Prevalence of type 2 diabetes
mellitus (T2DM) in the adult Russian population (NATION study).
Diabetes Res Clin Pract. 115:90–95. 2016.PubMed/NCBI View Article : Google Scholar
|
